Appointments at Catalent, Norwich Pharmaceuticals and Prism Ideas – People on the move

Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Catalent, Norwich Pharmaceuticals and Prism Ideas.

Catalent Pharma Solutions has made three appointments to strengthen its pharma manufacturing network. Jochen Roche, a former BASF employee, has been named country general manager, softgel manufacturing at Catalent Japan.

David Bricker has been appointed general manager, sterile technologies at Catalent’s Woodstock blow, fill and seal facility. Bricker has previously worked at Boehringer Ingelheim and AstraZeneca.

Finally, Sergio Alter, a former employee of Sandoz and Janssen-Cilag, has been appointed as general manager at Catalent Buenos Aires. Catalent recently expanded its Buenos Aires softgel manufacturing facility.

Prism Ideas has named Carol Hills as chief operations officer. Hills has more than 20 years of pharma experience at companies including Glaxo Group Research and AstraZeneca.

Terence Novak has joined Norwich Pharmaceuticals as president, commercial operations. Novak has previously worked at Bristol-Myers Squibb, DSM Pharmaceuticals and Patheon.

RSSL Pharma has hired Louis McMahon as pharmaceutical consultant. McMahon has 13 years of pharma manufacturing experience working at Novartis, Biovail, Wyeth and Pfizer.

Louis Weiner has been appointed vice president (VP) of sales and LLC member at A+ Secure Packaging. Weiner has previously worked at Catalent Pharma Solutions in his 27 years in the contract pharmaceutical packaging industry.

TGaS Advisors has added three senior level employees. Anna McClafferty has been named VP, management advisor, oversees marketing sciences, global marketing and executive commercial operations practices.

Also, Joe Falcon has joined as VP, management advisor, for the managed markets practice. Finally, Thomas “TJ” Scott has been appointed as director, management advisor, for the marketing sciences solution.

Synarc has strengthened its cardiac imaging trial services business by appointing Peter Milner, co-founder of CV Therapeutics, ARYx Therapeutics and Optivia Biotechnology.